reports
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of . Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streaml...
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that the U.S. FDA has renewed its licenses to the software platform. DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI). The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions. DILIsym predict...
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18.3 million Software revenue increased 11% to $11.6 million, representing 63% of total revenue Services revenue increased 27% to $6.7 million, representing 37% of total revenue Gro...
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings an...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this link t...
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Lif...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time. In addition, Mr. O’Connor will be meeting one-on-one with investors throughout the day. The live webcast of the Company’s presentation can be accessed via this and ...
Simulations Plus and the University of Bath Awarded New FDA Grant
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with the University of Bath’s Department of Life Sciences and other university partners, it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA). The grant will be used to expand and validate a multi-functional, multi-purpose physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling solution for topical product...
Simulations Plus Extends Collaboration with Major Toxicology Research ...
LANCASTER, Calif.--(BUSINESS WIRE)-- . (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced an extension to the formal agreement with the Translational Toxicology Division at the (NIEHS) to support the rapid safety assessment of chemicals in animals and humans. “At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health. The Division of Translational Toxicology (DTT) at NIEHS provides health effects resear...
Simulations Plus Launches Corporate Development Initiative
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships. Simulations Plus will actively pursue investments and partnerships in early-stage technology companies aimed at accelerating software and services innovations, increasing technology leadership in computational biology and chemistry, exp...
Simulations Plus to Participate in Upcoming Healthcare Conferences
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February. The Company will be presenting at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024. Shawn O’Connor, chief executive officer, will be presenting on Tuesday, February 13, 2024, at 11:20 a.m. Eastern Time, and he will be meeting with investors throughout both days. The li...
Simulations Plus Releases GastroPlus® Version 9.9
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Key enhancements include: Expanded the , , and models by adding new formulation and PK/PD mechanisms to better capture local and systemic exposure levels in animals and humans Extended the ACAT™ model to enhance the evaluation ...
Simulations Plus Embarks on Collaboration with Northeastern University...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with Northeastern University and The TIM Company, it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA). The project will aid in the understanding of oral modified-release (MR) formulations and advance the development and approval of generic oral MR drug products through the combination of novel in vitro testing and mechanistic...
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter fiscal 2024, ended November 30, 2023. First Quarter Financial Highlights Total revenue increased 21% to $14.5 million Software revenue increased 25% to $7.6 million, representing 52% of total revenue Services revenue increased 17% to $6.9 million, representing 48% of total revenue Gross profit increased 6% to $9.8 million; gr...
Simulations Plus Announces Leadership Appointments Supporting Commitme...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following leadership changes effective January 3, 2024. “We are excited to announce key strategic appointments that will advance our objective to seamlessly and organically align with our clients’ needs,” said Shawn O’Connor, Chief Executive Officer. “We have a deep bench of talent at Simulations Plus, and I am delighted to recognize the excellent leadership and accomplishments that each perso...
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this link ...
Simulations Plus Outlines Paths to Win at 2023 Investor Day
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today will host its investor day virtually, as previously announced. Chief Executive Officer Shawn O’Connor, Chief Financial Officer Will Frederick, and other members of the leadership team will present an in-depth review of the Company’s client-centric business model as well as outline how its new organizational structure better aligns its business with their clients and facilitates future ...
ISoP New Board of Trustees Members Announced
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that , Vice President of Pharmacometrics, has been elected to the International Society of Pharmacometrics (ISoP) Board of Trustees. “Amparo is an experienced pharmacometrician, having spent more than 20 years working for Eli Lilly and Company before going into consulting and serving small biotechs and big pharma companies in diverse therapeutic areas. Throughout her career, she has always sought ways to volunteer an...
Simulations Plus to Host Investor Day on Tuesday, November 14th
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it will hold a virtual Investor Day on Tuesday, November 14, 2023, beginning at 1:00 p.m. Eastern time. Presentations will be given by CEO Shawn O’Connor and members of the Simulations Plus leadership team who will share how putting customers first drives growth and fuels innovation. This event will be virtual, and attendance is b...
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Resu...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023. Fourth Quarter Financial Highlights Total revenue increased 33% to $15.6 million Software revenue increased 59% to $9.3 million, representing 60% of total revenue Services revenue increased 8% to $6.3 million, representing 40% of total revenue Gross profit increased 35% to $12.3 million; gross m...
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earning...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25, 2023. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this ...
Simulations Plus Receives New FDA Grant Award
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA). The grant will be used to validate and define best practices for physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling workflows to simulate virtual bioequivalence (VBE) studies in support of regulatory biowaivers. The scientific team at Simulations Plus, with partners from the F...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.